cagrisema semaglutide cagrilintide combination trial vs Retatrutide 2026: Approval & Data CagriSema Weight Loss: What Patients

Treatments for Diabetes in Florence, Italy, demonstrated.

Retatrutide RUO 40mg

In this post, we're diving into an exciting topic that merges science and natural remedies

In the SURPASS-4 trial, patients receiving tirzepatide experienced an average weight loss of 7.1 kg (15.7 lbs) after 52 weeks, compared to 2.5 kg (5.5 lbs) in the insulin glargine group[6]. The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes

Why Low FODMAP Matters for GLP-1 Support

The maintenance semaglutide dose was 1 mg in 16 cases and 2 mg in nine cases, leading to a similar weight loss of 13.6% (14.9 kg) and 12.8% (14 kg), respectively